An interventional study of HIV, HCV and overdose prevention in HIV Infections, HCV and Drug Overdose, sponsored by Johns Hopkins Bloomberg School of Public Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health — 1 open to participants now, 1 under way, none of them phase 3. HIV Infections · Johns Hopkins Bloomberg School of Public Health.
Among the 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 with no phase, and was the 17th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health is open now, in 1 country.
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 1
First in 1990; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 285 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 234 across the 19 interventional studies, 1,546 across the 2 observational. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 41 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
1 of the studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05320835Johns Hopkins Bloomberg School of Public HealthA Setting Focus Overdose Prevention Intervention | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).
This is a pilot of an injection setting targeted peer-driven intervention to reduce HIV/HCV transmission and overdose risk behaviors. Participants will be randomized to conditions: 1) Peer education and stocking of semi-public injection settings (SPIS) with risk reduction materials, and the standard of care. Based on their SPIS use, 120 index PWID participants will be selected.
A conceptual model for the intervention: The conceptual model is based on social influence, social network, and social cognitive theory. The prior work delineated social influence mechanisms. It is expected that training and modeling of effective communication skills will increase the occurrence of conversations on HIV/HCV and overdose prevention. These conversations will then alter perceived descriptive and prescriptive social norms of risk behaviors. The prior work is being enhanced by increasing the availability of risk reduction materials as well as the cuing and modeling risk reduction behaviors in risk settings. It has been found that PWID are motivated to conduct peer education; it enhances their status and provides them a prosocial role in the community. It is hypothesized that peer outreach and supply of materials to SPIS will lead to reduced sharing of injection equipment and increased naloxone availability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
behavioral training with 6 sessions
Behavioral: HIV, HCV and overdose prevention
Attention control
Behavioral: HIV, HCV and overdose prevention
HIV, HCV and overdose prevention
Overdose prevention
Frequency of carrying naloxone
Time frame: 6 months
HIV/HCV prevention
Frequency of using used cookers
Time frame: 6 months
Overdose behaviors
Frequency of testing drugs before using
Time frame: 6 months
Overdose behaviors 2
Frequency of talking about overdose prevention
Time frame: 6 months
Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 55 months is above that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins Bloomberg School of Public Health →